Summary:
Hanger Inc. has acquired Liberating Technologies Inc. to strengthen its research and innovation capabilities and accelerate development of next-generation prosthetic technologies.

Key Takeaways:

  • The acquisition enhances Hanger’s R&D ecosystem by integrating LTI’s government-funded research and advanced technology development.
  • LTI will continue key initiatives, including voice-controlled prosthetics, socket cooling systems, and improved electrode configurations for pattern recognition.
  • With prior acquisition of Coapt, Hanger now consolidates the full Coapt portfolio to drive innovation and improve patient outcomes.

Hanger Inc., a provider of orthotic and prosthetic (O&P) patient care services and solutions, announced the acquisition of Liberating Technologies Inc. (LTI), a research organization founded in 2000 and previously owned by Coapt. Since 2008, LTI’s specialized research team has secured numerous government-funded grants to pursue cutting-edge, high‑impact concepts and develop next‑generation technologies for the O&P field.

“The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence‑based care,” said Pete Stoy, Hanger’s Chief Executive Officer. “This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation.”

LTI will join Hanger Ventures and the Hanger Institute for Clinical Research and Education in driving innovation and accelerating progress in clinical care. The LTI team will continue leading its current grant‑funded initiatives—including advancing voice‑recognition technology for improved prosthesis control, developing socket cooling systems to support residual limb skin health, and optimizing electrode configurations for pattern recognition control to help prosthesis users achieve optimal functional outcomes—while also actively pursuing new research and development opportunities to expand the impact of their work.

“We are excited about this opportunity to become a part of the Hanger ecosystem, which will provide LTI with the technical resources, and the access to clinical insights and clinical data that can help us further drive and enhance innovation,” said Todd Farrell, PhD, vice president of research and development for Hanger. 

Hanger previously announced the acquisition of LTI’s previous owner Coapt in 2025, and with this acquisition, the full Coapt portfolio is now a part of the Hanger family. 

Featured image: Dreamstime